Bioanalysis of monomethyl fumarate in human plasma by a sensitive and rapid LC–MS/MS method and its pharmacokinetic application

S, Imam Pasha.; Varanasi, Murali Balaram; Mohammed, Ibrahim

doi:10.1016/j.jpba.2017.08.015

Cited by 5 publications

(1 citation statement)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the inherent complexity of biological matrices, samples are usually subjected to clean-up or preconcentration procedures to enrich the sample and to eliminate possible interferences that can hinder the determination of the compound(s) of interest. The complexity of such procedures ranges from simple dilution of the sample (dilute and shoot (DAS)) [17][18][19] or protein precipitation (PPT) [20,21] to intricate procedures dealing with solid-phase (SPE) [22][23][24] or liquid-liquid (LLE) [25] extractions [26,27]. It is clear that the sample treatment procedure is determined by the information available regarding the structural and the physicochemical properties of the analytes, the matrix, and the purpose of the analysis.…”

Section: Introductionmentioning

confidence: 99%

Ion Mobility–Mass Spectrometry for Bioanalysis

et al. 2021

View full text Add to dashboard Cite

This paper aims to cover the main strategies based on ion mobility spectrometry (IMS) for the analysis of biological samples. The determination of endogenous and exogenous compounds in such samples is important for the understanding of the health status of individuals. For this reason, the development of new approaches that can be complementary to the ones already established (mainly based on liquid chromatography coupled to mass spectrometry) is welcomed. In this regard, ion mobility spectrometry has appeared in the analytical scenario as a powerful technique for the separation and characterization of compounds based on their mobility. IMS has been used in several areas taking advantage of its orthogonality with other analytical separation techniques, such as liquid chromatography, gas chromatography, capillary electrophoresis, or supercritical fluid chromatography. Bioanalysis is not one of the areas where IMS has been more extensively applied. However, over the last years, the interest in using this approach for the analysis of biological samples has clearly increased. This paper introduces the reader to the principles controlling the separation in IMS and reviews recent applications using this technique in the field of bioanalysis.

show abstract

Section: Introductionmentioning

confidence: 99%

Ion Mobility–Mass Spectrometry for Bioanalysis

et al. 2021

View full text Add to dashboard Cite

show abstract

Multiple Sclerosis

Pitts

Dyckman

2021

Burger's Medicinal Chemistry and Drug Discovery

View full text Add to dashboard Cite

Several new medicines have been approved or entered development for the treatment of Multiple Sclerosis (MS) in the past few years. The sphingosine‐1‐phosphate (S1P) modulator fingolimod was the first FDA approved oral disease modifying therapy for MS, and it has inspired a number of additional agents directed at this clinically validated target. Fumarates (e.g. dimethyl fumarate), dihydroorotate dehydrogenase inhibitors (e.g. teriflunomide) and other agents which decrease lymphocyte proliferation (e.g. cladribine) represent additional clinically validated therapeutic approaches. While the mechanisms of action for these new agents may not be fully defined, they have demonstrated a good degree of efficacy in the treatment of relapsing forms of MS. It is of interest to note that biologic agents which target CD20 on B cells have also shown significant efficacy in the treatment of MS. This, in turn, has spurred MS clinical trials with Bruton's Tyrosine Kinase (BTK) inhibitors, which also act on B cell pathways. The introduction of each of these newer agents still requires careful consideration of the risk–benefit for individual patients, but has also set a higher bar in the treatment of MS for subsequent agents, as evidenced by the discontinuation of several agents in late stage clinical trials. This higher bar has also pushed some historic agents to second or third line agents. This speaks to an overall advancement in the treatment of MS, and provides hope for further advances in therapeutic options.

show abstract